Securing Profitability and Expanding the Healthcare Business
First written in FY2016. 3 of 11 entries say "Restated". Latest entry: 2026-07-31.
Kissei Pharmaceutical moved to the "Worse" side of this theme in 2025.
0 other companies' latest entry also says "Softened".
- FY2025SoftenedAnnual report
「Healthcare food products 3,553 0.2」
Healthcare food product sales were ¥3,553 million, up just 0.2% year on year, with the increase in sales narrowing from 2.4% in the previous fiscal year. - FY2025-H1AdvancedAnnual report
「Healthcare food sales 1,800」
Healthcare food sales were ¥1,800 million, up from ¥1,763 million in the same period of the previous year. - FY2024AdvancedAnnual report
「Healthcare food sales 3,545 2.4」
Healthcare food sales were ¥3,545 million, up 2.4% year on year, marking progress in revenue growth. - FY2022RestatedAnnual report
「In the healthcare food business, we will expand revenue by providing high-quality products.」
The policy of providing high-quality products in the healthcare food business to expand revenue was reconfirmed. - FY2020ReframedAnnual report
「In the healthcare food business, we will expand revenue by providing high-quality products.」
In addition to the existing focus on nursing care and elderly care, renal disease and the home healthcare market, the company indicated a direction of providing high-quality products in the healthcare food business to expand revenue. - FY2019RestatedAnnual report
「We will improve profitability by continuing to launch new products in the nursing care, elderly care and renal disease fields and establishing a competitive advantage in the home healthcare market.」
The policy of improving healthcare business profitability, centered on nursing care and elderly care, renal disease, and the home healthcare market, was reconfirmed. - FY2018RestatedAnnual report
「We will improve profitability by continuing to launch new products in the nursing care, elderly care and renal disease fields and establishing a competitive advantage in the home healthcare market.」
The policy of improving healthcare business profitability, centered on nursing care and elderly care, renal disease, and the home healthcare market, was reconfirmed. - FY2017ReframedAnnual report
「We will improve profitability by continuing to launch new products in the nursing care, elderly care and renal disease fields and establishing a competitive advantage in the home healthcare market.」
For the healthcare business, the focus has been made more specific, shifting from expansion into new therapeutic areas and target markets to establishing a competitive advantage in the home healthcare market and improving profitability. - FY2016First statedAnnual report
「We will secure revenue through the continued launch of new products and product improvements in the nursing care, elderly care and renal disease fields, while entering new therapeutic areas and expanding target markets.」
The company is pursuing revenue growth through new product launches and product improvements, entry into new therapeutic areas, and market expansion.